Blog Post
April 16, 2016

Nizar Tannir: How do I treat my patients with nccRCC?

From MD Anderson Cancer Survivors Conference, April 16, 2016

The Kidney Cancer Association held a "Survivors' Conference" on Saturday, April 16, 2016 at MD Anderson in Houston.

The KCA also kindly recorded a video (here).

I have reproduced particular slides of interest from Nizar Tannir's nccRCC presentation below:

  • How do I treat my patients with nccRCC?
    • Chromophobe: Responds to VEGFR-TKI / mTORi
    • RMC
      • Initial chemo as in TCC
      • Cytoreductive nephrectomy when feasible
      • Clinical Trials
    • Sarcomatoid: Gemcitabine based chemo +/- TKI; Clinical Trials (possibly highly responsive to immune checkpoint inhibitors)
    • All others
      • Clinical Trials
  • Ongoing Clinical Trials for Papillary RCC
  • Ongoing Clinical Trials for nccRCC
  • Conclusions
    • There is no established standard of care for nccRCC
      • Anti-VEGF TKIs are less effective in nccRCC compared with ccRCC
      • Temsirolimus is a poor standard of care for poor-risk disease
      • There may be a role for c-MET inhibitors in patients with germline mutation of c-MET in papillary RCC
      • The role of cytoreductive nephrectomy is not defined
    • All patients with metastatic nccRCC should be referred for enrollment on clinical trials
    • Data are now available from TCGA to develop rational targeted therapies based on relevant targets in chromophobe and papillary RCC
    • Transformative biology-driven trials are needed to improve clinical outcome
    • Trials with immune checkpoint inhibitors are planned


Add new comment

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.